A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia

Genes Chromosomes and Cancer

Volumn 44, Issue 3, 2005, Pages 329-333

  Griesinger, Frank ^a   Hennig, Heike ^a   Hillmer, Frauke ^a   Podleschny, Martina ^a   Steffens, Rainer ^a   Pies, Andreas ^a   Wörmann, Bernhard ^b   Haase, Detlef ^a   Bohlander, Stefan K ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Braunschweig Hospital   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION PROTEIN BCR JAK2; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BCR GENE; BCR JAK2 GENE; CASE REPORT; CHROMOSOME 22Q; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DIMERIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE LOCUS; GENE REARRANGEMENT; HUMAN; HUMAN CELL; JAK2 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; PYRIMIDINES; TRANSLOCATION, GENETIC;

EID: 25844469587     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20235     Document Type: Article

References (27)

1. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Hoglund M. 1997. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20:299-304.
2. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NC. 2002. The t(4;22)(q12;q11) in atypical chronic mycloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11:1391-1397.
3. Bohlander SK. 2000. Fusion genes in leukemia: an emerging network. Cytogenet Cell Genet 91:52-56.
4. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT, Bernard O, Ghysdael J. 2000. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95:3891-3899.
5. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, Koduru P, Brody JP, Hawson G, Rodwell R and others. 2001. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98:3778-3783.
6. Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M, Strombeck B, Olofsson T, Mitelman F, Johansson B. 2003. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 32:302-310.
7. Fitzgerald PH, Morris CM. 1991. Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? Cancer Genet Cytogenet 57:143-151.
8. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316.
9. Grand EK, Grand FH, Chase AJ, Ross FM, Corcoran MM, Oscier DG, Cross NC. 2004a. Identification of a novel gene, FGFR 1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 40:78-83.
10. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, Chase AJ, Cross NC. 2004b. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;35)(q33;q22) and an imatinib-responsive eosinophilic myelo-proliferative disorder. Cancer Res 64:7216-7219.
11. Griesinger F, Janke A, Podleschny M, Bohlander SK. 2002. Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br J Haematol 119:454-458.
12. Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W, Wormann B. 1995. Evidence for malignant transformation in acute myeloid leukemia at ehe level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86:2906-2912.
13. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC. 2000. Fusion of H4/ D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferacive disorders with a t(5;10) (q33;q21). Cancer Res 60:3592-3598.
14. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. 1997. A TEL-JAK2 fusion protein wich constitutive kinase activity in human leukemia. Science 278:1309-1312.
15. Leonard WJ, O'Shea JJ. 1998. Jaks and STATs: biological implications. Annu Rev Immunol 16:293-322.
16. Li S, Ilaria RL, Jr., Million RP, Daley GQ, Van Etten RA. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399-1412.
17. McWhirter JR, Wang JY. 1991. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/ abl fusion proteins. Mol Cell Biol 11:1553-1565.
18. McWhirter JR, Galasso DL, Wang JY. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587-7595.
19. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9:12) in a lymphoid and t(9:15;12) in a myeloid leukemia. Blood 90:2535-2540.
20. Popovici C, Adelaide J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M, Leroux D, Birnbaum D, Pebusque MJ. 1998. Fibroblast growth factor receptor 1 is fused to F1M in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 95:5712-5717.
21. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, Cross NC. 1998. Consistent fusion of ZKF198 to the fibroblast growth factor receptor-1 in the t(S;13)(p11;q12) myeloproliferative syndrome. Blood 92:1735-1742.
22. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Marynen P, Gilliland DG. 1998. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferacive disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17:5321-5333.
23. Smedley D, Hamoudi R, Clark J, Warren W. Abdul-Rauf M, Somers G, Venter D, Fagan K, Cooper C, Shipley J. 1998. The t(8:13)(p11:q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 7:637-642.
24. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, Van Roy N, Marynen P, De Paepe A, Slater R, Speleman F. 2001. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 30: 274-282.
25. Vizmanos JL, Hernandez R, Vidal MJ, Larrayoz MJ, Odero MD, Marin J, Ardanaz MT, Calasanz MJ, Cross NC. 2004a. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J 5:534-537.
26. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC. 2004b. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 64:2673-2676.
27. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA. 1998. FGFR1 is fused with a novel zinc-finger gene. ZNF198, in the t(8:13) leukaemia/ lymphoma syndrome. Nat Genet 18:84-87.